CoChat

Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness

Thomas, Rejish K, Baker, Glen, Lind, John, Dursun, Serdar · 2018 · Journal of Psychopharmacology

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Background Intravenous ketamine has been established as an efficacious and safe treatment, with transient effect, for treatment-resistant depression. However, the effectiveness of intravenous ketamine in non-research settings and with ultraresistant depression patients remains understudied. Aims This study aims to measure the response and remission rates in ultraresistant depression patients in a clinical setting by means of a retrospective, open label, database study. Secondarily, the study will attempt to support previous findings of clinical predictors of effectiveness with intravenous ketamine treatment. Methods Fifty patients with ultraresistant depression were treated between May 2015-December 2016, inclusive, in two community hospitals in Edmonton using six ketamine infusions of 0.5 mg/kg over 40 min over 2-3 weeks. Data were collected retrospectively from inpatient and outpatient charts. Statistical analysis to investigate clinical predictors of effectiveness included logistic regression analysis using a dependent variable of a 50% reduction in rating scale score at any point during treatment. Results At baseline, the average treatment resistance was severe, with a Maudsley Staging Method score of 12.1 out of 15, 90.0% were resistant to electroconvulsive therapy, and the average Beck Depression Inventory score was 34.2. The response rate was 44% and remission rate was 16%. As a single predictor, moderate or severe anhedonia at baseline predicted a 55% increased likeli…

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881118793104

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 64 references

Research works printed but not linked: 2

  1. Beck AT, 1996, Beck Depression Inventory-Second Edition (BDI-II)
  2. 10.1176/appi.pn.2016.PP10b2 · doi:10.1176/appi.pn.2016.pp10b2

Cited by

See all 69

Metadata

Authors
Thomas, R. K., Baker, G., Lind, J., & Dursun, S.
Affiliations
University of Alberta (CA)
Corresponding author
Thomas, Rejish K
Venue
Journal of Psychopharmacology
Published
2018-09-05
Volume
32
Issue
10
Pages
1110-1117
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2890154361
Cited by
69
References
64
Citations by year
2026: 3 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 24 · 2021: 9 · 2020: 6 · 2019: 8
FWCI
3.71
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Alberta
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
intravenous ketamine, treatment-resistant depression, anhedonia, bipolar depression, predictors of treatment response, remission
MeSH terms
Adult, Aged, Antidepressive Agents, Female, Hospitals, Community, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Remission Induction, Retrospective Studies, Severity of Illness Index, Databases, Factual, Treatment Outcome, Excitatory Amino Acid Antagonists, Anhedonia, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. https://app.cochat.ai/papers/10.1177/0269881118793104
The paper
Thomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018). Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. Journal of Psychopharmacology. https://doi.org/10.1177/0269881118793104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.